JP6817943B2 - 分化転換方法及びその使用方法 - Google Patents

分化転換方法及びその使用方法 Download PDF

Info

Publication number
JP6817943B2
JP6817943B2 JP2017535829A JP2017535829A JP6817943B2 JP 6817943 B2 JP6817943 B2 JP 6817943B2 JP 2017535829 A JP2017535829 A JP 2017535829A JP 2017535829 A JP2017535829 A JP 2017535829A JP 6817943 B2 JP6817943 B2 JP 6817943B2
Authority
JP
Japan
Prior art keywords
cells
cell
expression
transdifferentiation
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017535829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502574A (ja
JP2018502574A5 (enExample
Inventor
ファーバー、サラ
Original Assignee
オージェネシス リミテッド
オージェネシス リミテッド
テル ハシュオマー−メディカル リサーチ インフラストラクチャー アンド サービシーズ リミテッド
テル ハシュオマー−メディカル リサーチ インフラストラクチャー アンド サービシーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オージェネシス リミテッド, オージェネシス リミテッド, テル ハシュオマー−メディカル リサーチ インフラストラクチャー アンド サービシーズ リミテッド, テル ハシュオマー−メディカル リサーチ インフラストラクチャー アンド サービシーズ リミテッド filed Critical オージェネシス リミテッド
Publication of JP2018502574A publication Critical patent/JP2018502574A/ja
Publication of JP2018502574A5 publication Critical patent/JP2018502574A5/ja
Application granted granted Critical
Publication of JP6817943B2 publication Critical patent/JP6817943B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
JP2017535829A 2014-12-30 2015-12-30 分化転換方法及びその使用方法 Expired - Fee Related JP6817943B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098050P 2014-12-30 2014-12-30
US62/098,050 2014-12-30
PCT/IL2015/051267 WO2016108237A1 (en) 2014-12-30 2015-12-30 Methods of transdifferentiation and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018502574A JP2018502574A (ja) 2018-02-01
JP2018502574A5 JP2018502574A5 (enExample) 2018-03-15
JP6817943B2 true JP6817943B2 (ja) 2021-01-20

Family

ID=56284403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535829A Expired - Fee Related JP6817943B2 (ja) 2014-12-30 2015-12-30 分化転換方法及びその使用方法

Country Status (15)

Country Link
US (3) US10179151B2 (enExample)
EP (2) EP3240576B1 (enExample)
JP (1) JP6817943B2 (enExample)
KR (1) KR102487883B1 (enExample)
CN (1) CN107750170B (enExample)
AU (1) AU2015373129B2 (enExample)
BR (1) BR112017014280A2 (enExample)
CA (1) CA2972569A1 (enExample)
CO (1) CO2017006937A2 (enExample)
EA (1) EA035360B1 (enExample)
IL (1) IL253234B (enExample)
MA (1) MA41296A (enExample)
MX (1) MX378321B (enExample)
SG (1) SG11201705344VA (enExample)
WO (1) WO2016108237A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510209SA (en) 2013-06-13 2016-01-28 Orgenesis Ltd Cell populations, methods of transdifferention and methods of use thereof
US10231817B2 (en) 2013-09-24 2019-03-19 Giner Life Sciences, Inc. System for gas treatment of a cell implant
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
WO2017192717A1 (en) 2016-05-05 2017-11-09 Southwest Research Institute Three-dimensional bioreactor for cell expansion and related applications
US11033666B2 (en) 2016-11-15 2021-06-15 Giner Life Sciences, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
WO2018204867A1 (en) 2017-05-04 2018-11-08 Giner, Inc. Robust, implantable gas delivery device and methods, systems and devices including same
EP3635106A4 (en) 2017-05-08 2021-01-06 Orgenesis Ltd. POPULATIONS OF TRANSDIFFERENTIATED CELLS AND THEIR METHODS OF USE
WO2018220623A1 (en) * 2017-05-29 2018-12-06 Orgenesis Ltd. Compositions and methods for providing cell replacement therapy
JP2020537522A (ja) 2017-10-13 2020-12-24 イーエムベーアー−インスティテュート フュール モレクラレ バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 体細胞の増強された再プログラミング
WO2019171377A1 (en) * 2018-03-06 2019-09-12 Orgenesis Inc Three dimensional clusters of transdifferentiated cells, compositions and methods thereof
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
WO2020068840A1 (en) 2018-09-24 2020-04-02 Southwest Research Institute Three-dimensional bioreactors
EP3816276A1 (en) * 2019-10-31 2021-05-05 Unicyte Islet AG Viable pancreatic islet-like cell structures and a method of preparing thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427940A (en) 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE69435026D1 (de) 1993-08-16 2007-10-31 Res Dev Foundation Ein homeobox-faktor der insulin-expression in pankreatischen inselnzellen stimuliert
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
JP2000501290A (ja) 1995-11-30 2000-02-08 リサーチ ディベロップメント ファンデーション ソマトスタチン及びインシュリン生成を刺激する化合物のスクリーニング・アッセイ
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
JP2000513227A (ja) 1996-06-24 2000-10-10 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド インスリン分泌細胞の単離および増殖方法
US6114113A (en) 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
CA2221195A1 (en) 1997-11-14 1999-05-14 Chantal E. Holy Biodegradable polymer matrix
US6143293A (en) 1998-03-26 2000-11-07 Carnegie Mellon Assembled scaffolds for three dimensional cell culturing and tissue generation
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
US6759039B2 (en) 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
US7214371B1 (en) 2000-09-01 2007-05-08 Ben-Gurion University Of The Negev Research & Development Authority Tissue engineered biografts for repair of damaged myocardium
US7524492B2 (en) 2001-08-31 2009-04-28 Joslin Diabetes Center, Inc. Insulin related transcription factor and uses thereof
US20050053588A1 (en) 2001-10-18 2005-03-10 Li Yin Conversion of liver stem and progenitor cells to pancreatic functional cells
US7722894B2 (en) 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
GB2399823B (en) 2001-12-07 2006-02-15 Geron Corp Islet cells from primate pluripotent stem cells
WO2003072728A2 (en) * 2002-02-22 2003-09-04 University Of Florida Cellular trans-differentiation
GB0206357D0 (en) 2002-03-18 2002-05-01 Univ Bath Cells
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
CN1662643A (zh) 2002-05-28 2005-08-31 贝克顿·迪金森公司 人腺泡细胞的扩增和转分化
MXPA05011896A (es) 2003-05-05 2006-05-25 Univ Ben Gurion Preparaciones polimericas reticuladas inyectables y sus usos.
EP1624898A1 (en) * 2003-05-12 2006-02-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
WO2005005607A2 (en) 2003-06-30 2005-01-20 Lifescan, Inc. Seeding pancreatic cells on porous matrices
AU2004269395A1 (en) 2003-08-27 2005-03-10 Stemcells California, Inc. Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2005056747A2 (en) 2003-12-09 2005-06-23 Ben-Gurion University Of The Negev Research And Development Authority Pulse-medium perfusion bioreactor with improved mass transport for multiple 3-d cell constructs
EP1784481A1 (en) 2004-08-25 2007-05-16 Technion Research And Development Foundation, Ltd. Methods of generating embryoid bodies using three dimensional scaffolds
US8679484B2 (en) 2005-03-02 2014-03-25 Polyrizon Ltd. Method for removal of toxins from mucosal membranes
US9216236B2 (en) 2005-03-07 2015-12-22 Technion Research & Development Foundation Limited Natural tissue-derived decellularized matrix and methods of generating and using same
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
US20100137202A1 (en) * 2006-07-19 2010-06-03 University Of Florida Research Foundation Compositions for reprogramming a cell and uses therefor
AU2007335753B2 (en) 2006-12-18 2013-12-05 Ben Gurion University Of The Negev Scaffolding for tissue regeneration or repair
US20100226976A1 (en) 2007-07-11 2010-09-09 Marcelle Machluf Encapsulated mesenchymal stem cells and uses thereof
IL187707A0 (en) 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
WO2009126927A2 (en) 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Methods of generating insulin-producing cells
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
JP5717253B2 (ja) 2009-08-02 2015-05-13 学校法人東京女子医科大学 膵島細胞シート、製造方法及びその利用方法
AU2010312240B2 (en) * 2009-10-31 2016-12-15 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
JP2011223993A (ja) 2010-03-30 2011-11-10 Kumamoto Univ 幹細胞の分化誘導方法
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
EP2741753A2 (en) 2011-08-09 2014-06-18 Yeda Research and Development Co. Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013124855A1 (en) 2012-02-21 2013-08-29 Ben-Gurion University Of The Negev Research And Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
WO2014102801A1 (en) 2012-12-30 2014-07-03 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
KR102757386B1 (ko) 2013-05-08 2025-01-21 인리젠 단리된 신장 세포를 포함하는 오가노이드 및 이의 용도
SG11201510209SA (en) * 2013-06-13 2016-01-28 Orgenesis Ltd Cell populations, methods of transdifferention and methods of use thereof
EP3107549B1 (en) 2014-02-20 2020-07-01 B.G. Negev Technologies and Applications Ltd. Anionic polyplexes for use in the delivery of nucleic acids
CA2950132C (en) 2014-05-30 2022-01-18 The Secant Group, Llc Water-mediated preparations of polymeric materials
WO2015186127A1 (en) 2014-06-02 2015-12-10 B. G. Negev Technologies And Applications Ltd Site-selective modification of polysaccharides and applications thereof
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3400074B1 (en) 2016-01-07 2021-10-20 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Compositions for generating immunotolerant responses
US20170290954A1 (en) 2016-04-07 2017-10-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions and methods for treating spinal cord injury
WO2017175229A1 (en) 2016-04-07 2017-10-12 B.G. Negev Technologies And Applications Ltd. Polysaccharide compositions and uses thereof
EP3635106A4 (en) 2017-05-08 2021-01-06 Orgenesis Ltd. POPULATIONS OF TRANSDIFFERENTIATED CELLS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
CN107750170A (zh) 2018-03-02
US20200297777A1 (en) 2020-09-24
EA201791508A1 (ru) 2018-05-31
KR102487883B1 (ko) 2023-01-11
CA2972569A1 (en) 2016-07-07
US11617769B2 (en) 2023-04-04
EP3240576A4 (en) 2018-06-20
US10668107B2 (en) 2020-06-02
AU2015373129B2 (en) 2021-07-15
SG11201705344VA (en) 2017-07-28
AU2015373129A1 (en) 2017-08-03
JP2018502574A (ja) 2018-02-01
IL253234A0 (en) 2017-08-31
EA035360B1 (ru) 2020-06-02
KR20170102308A (ko) 2017-09-08
BR112017014280A2 (pt) 2018-03-27
EP3698803B1 (en) 2023-03-08
US20160220616A1 (en) 2016-08-04
CO2017006937A2 (es) 2017-10-20
EP3240576A1 (en) 2017-11-08
IL253234B (en) 2020-04-30
EP3240576B1 (en) 2020-03-04
EP3698803A1 (en) 2020-08-26
WO2016108237A1 (en) 2016-07-07
MX2017008669A (es) 2018-02-16
US20190134097A1 (en) 2019-05-09
CN107750170B (zh) 2021-10-08
US10179151B2 (en) 2019-01-15
MX378321B (es) 2025-03-10
MA41296A (fr) 2017-11-07

Similar Documents

Publication Publication Date Title
JP6817943B2 (ja) 分化転換方法及びその使用方法
US10975354B2 (en) Transdifferentiated cell populations and methods of use thereof
JP6650393B2 (ja) 細胞の集団、分化転換の方法及びその使用方法
WO2018220623A1 (en) Compositions and methods for providing cell replacement therapy
IL195114A (en) A monocyte-derived islet cell (mdi), a method for its creation, and its use in the preparation of a drug to treat diabetes
CN115120600A (zh) 薯蓣皂苷元及其类似物在制备预防或治疗糖尿病药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201225

R150 Certificate of patent or registration of utility model

Ref document number: 6817943

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees